BAJAJ BROKING
Orchid Pharma’s Alathur API facility completed a USFDA inspection with seven minor observations, ensuring continued compliance. The facility also renewed its EU GMP certification. Read more..Orchid Pharma share price rose 1.2%, closing at ₹828.25 on the BSE after the announcement. Read less
Orchid Pharma Ltd. has successfully completed an inspection by the United States Food and Drug Administration (USFDA) at its Active Pharmaceutical Ingredient (API) manufacturing facility in Alathur, Tamil Nadu. The inspection, which took place between 10 February and 18 February 2025, resulted in seven minor observations. None of these issues relate to data integrity, ensuring continued compliance with USFDA standards.
Also read: RITES Signs MoU with CWPRS for Water Resources & Infrastructure Projects
Orchid Pharma’s API facility in Alathur underwent a USFDA inspection from 10-18 February 2025.
The inspection resulted in seven minor observations, none concerning data integrity.
The facility retained its status as India’s only USFDA-approved site for sterile cephalosporins.
Orchid Pharma also renewed its European Union Good Manufacturing Practice (EU GMP) certification.
Orchid Pharma share price rose 1.2%, closing at ₹828.25 on the BSE after the announcement.
Also read: India Glycols Secures ₹1,264.2 Crore Ethanol Supply Order from OMCs
The Alathur facility plays a crucial role in Orchid Pharma’s manufacturing operations, particularly in the production of sterile cephalosporin antibiotics. This successful USFDA inspection ensures that the facility continues to meet international regulatory standards, reinforcing its position in key global markets.
In addition to the USFDA clearance, Orchid Pharma also renewed its European Union Good Manufacturing Practice (EU GMP) certification. This certification enables the company to maintain exports to European markets while adhering to stringent pharmaceutical manufacturing regulations.
Inspection Details | Outcome |
Inspection Period | 10-18 February 2025 |
USFDA Observations | 7 minor issues |
Data Integrity Concerns | None |
Facility Certification | USFDA & EU GMP renewed |
Speciality | Sterile cephalosporins |
Following the announcement of the successful inspection, Orchid Pharma share price saw a positive reaction in the stock market. The stock closed 1.2% higher at ₹828.25 on the BSE, reflecting investor confidence in the company’s regulatory compliance and international market stability.
With continuous adherence to global pharmaceutical standards, Orchid Pharma remains a key player in the API sector. The Orchid Pharma share price is expected to stay under close watch as the company strengthens its position in international markets.
Orchid Pharma’s ability to clear regulatory inspections and maintain international certifications reinforces its credibility in the global pharmaceutical industry. The successful USFDA inspection and EU GMP renewal further solidify its manufacturing capabilities, keeping its market outlook stable and investor confidence strong.
Also read: HFCL Secures Rs. 2,501.30 Crore BharatNet Phase-III Deal with BSNL
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading